Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue remains negative
Q1 FY2026 revenue was $4.58M, compared with $0 a year earlier. Trailing-twelve-month revenue was $16.72M.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 2 analysts of $20.77M (+71.1%) for the fiscal year ending Dec 2026, a slowdown from the +73.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $4.58M-18.8% QoQ
- Last fiscal yearDec 2025
- $12.14M+73.4% YoY
- LTMMar 2026
- $16.72M+138.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | +73.4% | +71.1% | -2.3 pp |
| 3-year CAGR | — | +102.0% | — |
| 5-year CAGR | +52.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 12.14M USD
- Year-over-year change
- +73.4%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.14M | +73.4% |
| FY2024 | 2024-12-31 | 7M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Revenue vs competitors
How PRLD compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +138.9% is the 2nd highest of 7, against a peer median of +10.2%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $69.21M USD | +7.4% | -8.8% | |
| LTM Mar 2026 | $32.72M USD | +1033.9% | +111.6% | |
| LTM Mar 2026 | $28.22M USD | +20.1% | +17.1% | |
| LTM Mar 2026 | $16.72M USD | +138.9% | — | |
| LTM Mar 2026 | $13.86M USD | — | — | |
| LTM Mar 2026 | $11.2M USD | +13.0% | -7.0% | |
| FY2025 | €4.48M EUR | -51.3% | -28.3% | |
| LTM Mar 2026 | $225K USD | — | — | |
| LTM Mar 2026 | $59K USD | -86.6% | -85.2% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $0 USD | — | — |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding PRLD) | — | +10.2% | -7.9% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7M | 12.14M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.71M |
| Gross Profit | 0 | 0 | 0 | 7M | 10.43M |
| Gross Margin | — | — | — | 100.0% | 85.9% |
| Research & Development | 86.78M | 92.89M | 103.39M | 118M | 94.3M |
| Selling, General & Admin | 26.96M | 30.65M | 28.88M | 28.72M | 22.41M |
| Operating Expenses | 113.74M | 123.54M | 132.28M | 146.71M | 115M |
| Depreciation & Amortization | 915K | 1.32M | 1.17M | 1.77M | 1.71M |
| EBITDA | (110.78M) | (114.11M) | (120.66M) | (125.4M) | (97.79M) |
| EBITDA Margin | — | — | — | -1791.4% | -805.5% |
| Operating Income | (113.74M) | (123.54M) | (132.28M) | (139.71M) | (104.57M) |
| Operating Margin | — | — | — | -1995.9% | -861.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 2.04M | 8.1M | 10.44M | 12.54M | 5.07M |
| Income Before Tax | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Pre-Tax Margin | — | — | — | -1816.8% | -819.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Net Margin | — | — | — | -1816.8% | -819.6% |
| EPS (Basic) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| EPS (Diluted) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| Weighted Avg Shares | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
| Weighted Avg Shares (Diluted) | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.